Back to Authors

Ferreira, InĂªs M.

https://orcid.org/0000-0003-3870-4460

A5019649517 | I129774422

Mayo Clinic

Ares Genetics GmbH, Vienna, Austria

Citations 2

Multicenter Evaluation of the Unyvero Platform for Testing Bronchoalveolar Lavage Fluid

Journal of Clinical Microbiology | December 16, 2020 | Volume: 59 | Issue: 3 | Pages: No page available

10.1128/jcm.02497-20 | PMID 33328178

Bronchoalveolar lavage (BAL) culture is a standard, though time-consuming, approach for identifying microorganisms in patients with severe lower respiratory tract infections. The sensitivity of BAL culture is relatively low, and prior antimicrobial therapy decreases the sensitivity further, leading to overuse of empirical antibiotics.
Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial

Journal of Clinical Microbiology | April 11, 2020 | Volume: 58 | Issue: 7 | Pages: No page available

10.1128/jcm.00273-20 | PMID 32295890

Whole-genome sequencing (WGS) is now routinely performed in clinical microbiology laboratories to assess isolate relatedness. With appropriately developed analytics, the same data can be used for prediction of antimicrobial susceptibility. We assessed WGS data for identification using open-source tools and antibiotic susceptibility testing (AST) prediction using ARESdb compared to matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) identification and broth microdilution phenotypic susceptibility testing on clinical isolates from a multicenter clinical trial of the FDA-cleared Unyvero lower respiratory tract infection (LRTI) application (Curetis).